Company Overview - Exegenesis Bio has submitted a listing application to the Hong Kong Stock Exchange, with CCB International as the sole sponsor [1] - The company specializes in gene therapy and oligonucleotide drugs, possessing globally leading delivery vector technology according to Frost & Sullivan [1] - Exegenesis Bio has developed proprietary platforms AAVarta (AI-assisted AAV capsid evolution discovery platform) and SODA (silencing oligonucleotide design method) [1] Key Products - The core candidate product EXG001-307 (for SMA type 1) aims to be the best-in-class therapy for spinal muscular atrophy (SMA) type 1, having received IND approval from the National Medical Products Administration in June 2022 and completed Phase I/II clinical trials in China [1] - Key candidate products EXG102-031 (AAV gene therapy for wet age-related macular degeneration, wAMD) and EXG202 (AAV gene therapy for retinal neovascular diseases including wAMD) aim to overcome the limitations of existing anti-VEGF biologics [1] Market Potential - The global gene therapy market is projected to grow from approximately $2.8 billion in 2024 to $32 billion by 2035 [2] - The Chinese gene therapy market is expected to reach RMB 11.6 billion by 2035 [2] - The global SMA drug market is anticipated to increase from $4.6401 billion in 2024 to $9.4469 billion by 2035 [2] - The Chinese SMA drug market is projected to grow from RMB 550.9 million in 2024 to RMB 3.2945 billion by 2035 [2]
Exegenesis Bio递表港交所 建银国际为独家保荐人
Zheng Quan Shi Bao Wang·2026-01-15 01:12